2743. Safety of Recombinant Influenza Vaccine Compared with Inactivated Influenza Vaccine in Adults

BACKGROUND: In 2013, a recombinant trivalent influenza vaccine (RIV, Flublok®, Sanofi Pasteur) was licensed for use against influenza virus subtypes A and B contained in the vaccine for persons 18–49 years of age and approved for all adults ≥18 years of age in 2014. The study aim was to evaluate the...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Open Forum Infect Dis
Hauptverfasser: Hansen, John, Goddard, Kristin, Timbol, Julius, Zhang, Lea, Lewis, Ned, Klein, Nicola
Format: Artigo
Sprache:Inglês
Veröffentlicht: Oxford University Press 2019
Schlagworte:
Abstracts
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6810428/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofz360.2420
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge